El efecto placebo es un evento fisiológico real. Cuando una persona espera alivio, ha sido condicionada por tratamientos anteriores y recibe atención cuidadosa, los propios sistemas reguladores del cuerpo se activan. Un placebo libera dopamina en la enfermedad de Parkinson y las propias opioides del organismo contra el dolor. Explica gran parte de la mejoría que las personas obtienen con los antidepresivos.
En ensayos rigurosos, alivió la fatiga relacionada con el cáncer incluso cuando a las personas se les informó que la pastilla no contenía ningún fármaco. La misma fisiología opera en sentido contrario en el efecto nocebo. Lo que un placebo modifica es cómo una persona se siente y funciona: no reduce un tumor, no baja una lectura de glucosa en sangre ni une un hueso roto.
Findings & Outcomes
What It Is
A placebo response is an improvement produced by the context of a treatment: the pill, the ritual, the practitioner's attention, and the expectation of getting better. Two mechanisms drive it. Expectation changes what the nervous system does next. Conditioning is learned: pairing a dummy treatment with a real drug effect enough times teaches the body to reproduce part of that effect on its own.
The effect is largest for symptoms the brain itself produces and controls: pain, depression, anxiety, nausea, fatigue, irritable bowel, and the motor symptoms of Parkinson's disease.
A placebo moves how a person feels and functions. It does not shrink a tumor, lower a blood sugar reading, or knit a broken bone.
Two terms get confused, and good research separates them by comparing a placebo group with an untreated group.
- The placebo response is everything that improves after an inert treatment. It includes the illness running its natural course and the tendency of extreme symptoms to drift back toward average, an artifact called regression to the mean.
- The placebo effect is the part caused specifically by expectation and context.
What remains after subtracting the illness's natural course is the placebo effect itself.
What the Evidence Shows
People given a pill openly described as inert, containing no drug, still improved more than people given no treatment. Three open-label trials show the size.
- Irritable bowel syndrome: patients told plainly their pills were placebos scored 5.0 on the IBS Global Improvement Scale, a 1-to-7 scale, over three weeks. An untreated group scored 3.9.
- Chronic low back pain added to usual care: composite pain dropped 1.5 points on a 0-to-10 scale, against 0.2 with usual care alone.
- Cancer survivors: fatigue fell by about 29% from baseline.
Pooling 11 of these open-label trials across conditions gave a significant overall effect, a standardized mean difference of 0.72 (von Wernsdorff 2021). The trials are mostly small, short, and measured by self-reported scales, so the long-term size of the effect is not known. The benefit is clearest for brain-mediated symptoms.
The pattern extends to depression. In an analysis of the antidepressant trial data submitted to US regulators, most of the improvement people got on the drugs was matched by improvement on placebo. The drug–placebo gap was clear only in the most severely depressed patients, mostly because the placebo response was weaker there.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Mood & stress
Placebo matched most of the antidepressant response, the drug ahead mainly in severe depression
In depression trials, most of the improvement people got on antidepressants also happened on placebo. The drug clearly outperformed placebo mainly in the most severe cases, where the placebo response was smaller.
A meta-analysis of clinical-trial data submitted to the US regulator (including unpublished trials) examined how the antidepressant-versus-placebo difference varied with baseline severity. Both drug and placebo groups improved substantially; the difference between them met a standard threshold for clinical significance only at the highest severity levels, and this widening gap was driven mostly by a diminishing placebo response in severe depression, not a rising drug response. The finding measures how large the placebo component of the response is, not that antidepressants are ineffective.
The study · 1
Kirsch et al. 2008, PLoS Med · PLoS Med
How it works
Blocking opioid receptors with naloxone cancels much of placebo pain relief
A lot of placebo pain relief runs on the body's own opioids. Block those receptors with a drug and the relief largely disappears; brain scans show the placebo using the same pain-control circuit as morphine.
Two complementary lines establish the mechanism. In post-surgical dental pain, administering naloxone (an opioid receptor antagonist) abolished much of the analgesia produced by placebo, implicating endogenous opioids (Levine 1978). Decades later, functional MRI combined with naloxone showed that placebo analgesia activates the descending opioidergic pain-modulatory system, from the rostral anterior cingulate cortex through the periaqueductal gray to the rostral ventromedial medulla, and that naloxone reduces both the behavioral and the neural placebo response (Eippert 2009). Together they show placebo pain relief is a real, opioid-dependent neurobiological process.
The studies · 2
Levine, Gordon & Fields 1978, Lancet · Lancet
Eippert et al. 2009, Neuron · Neuron
Open-label placebo helped on average across 11 pooled randomized trials
Pulling together the trials where people knew they were taking a placebo, the pills still helped on average across a range of conditions.
A systematic review and meta-analysis reviewed 13 randomized controlled trials of open-label placebo (openly described inert treatment) and pooled 11 of them across a spread of conditions and found a significant positive effect overall in favor of open-label placebo compared with no treatment. Effects were clearest for self-reported, brain-mediated symptoms. The authors note the trials are mostly small, short, and heterogeneous, so the pooled estimate establishes that the effect is real and reproducible without fixing a precise size.
The study · 1
von Wernsdorff et al. 2021, Sci Rep · Sci Rep
A placebo released the brain's own dopamine in Parkinson's disease
When Parkinson's patients thought they were getting their real drug, their brains released dopamine, the very chemical the disease lacks, just from expecting to improve.
Using positron emission tomography with raclopride to index dopamine release, researchers found that placebo administration in patients with Parkinson's disease produced marked release of endogenous dopamine in the dorsal and ventral striatum. The response was linked to the patients' expectation of therapeutic benefit and to activity in reward circuitry. It is a small mechanistic imaging study, and it provided direct biological evidence that a placebo response engages a specific, disease-relevant neurochemical system.
The study · 1
Placebo effects are real psychobiological events, several mechanisms not one
The experts who pull the whole field together conclude the placebo effect is real biology, driven by expectation and learning, working through several brain systems, and that it differs from condition to condition.
Dos revisiones importantes consolidan el campo. Una revisión en The Lancet describe los efectos placebo como eventos psicobiológicos atribuibles al contexto terapéutico, producidos por la expectativa y el condicionamiento clásico, y advierte que no son una molestia que deba descartarse (Finniss 2010). Una revisión en Nature Reviews Neuroscience traza la neurociencia: cómo el contexto y el aprendizaje moldean los resultados de salud, los sistemas opioide y dopaminérgico implicados, la variación individual y la contraparte nocebo (Wager 2015). Ambas enmarcan el placebo como varios procesos mecanísticamente distintos, no un efecto uniforme.
The studies · 2
Finniss et al. 2010, Lancet · Lancet
Wager & Atlas 2015, Nat Rev Neurosci · Nat Rev Neurosci
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Nocebo: la expectativa negativa produce síntomas reales y empeora el dolor
Esperar un daño puede causar síntomas reales. Ser advertido de que un tratamiento puede causar dolor o náuseas hace que esos síntomas sean más probables y más intensos, a través de los mismos sistemas cerebrales que impulsan el efecto placebo.
Las revisiones de la literatura sobre placebo documentan la contraparte nocebo: la sugerencia verbal de un resultado negativo, o una experiencia negativa previa, produce un empeoramiento de los síntomas, incluyendo un aumento del dolor (hiperalgesia), náuseas y fatiga, con cambios medibles en la colecistocinina, las vías dopaminérgicas y otras. Una consecuencia práctica es que una gran parte de los efectos adversos reportados por los pacientes con medicación activa también aparecen en los brazos de placebo de los ensayos, lo que indica un componente impulsado por la expectativa. El efecto nocebo muestra que el mecanismo es bidireccional.
The studies · 2
Wager & Atlas 2015, Nat Rev Neurosci · Nat Rev Neurosci
Finniss et al. 2010, Lancet · Lancet
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
El efecto nocebo explica alrededor del 90 % de la carga de efectos secundarios de las estatinas (ensayo cruzado SAMSON)
Personas que habían dejado las estatinas por efectos secundarios tomaron el fármaco real, una pastilla ficticia y nada, en meses aleatorios. Sus síntomas fueron casi tan intensos con la pastilla ficticia como con la estatina, por lo que alrededor del 90 % de lo que atribuían al fármaco también ocurrió con el placebo.
El ensayo SAMSON dio a 60 participantes que habían abandonado las estatinas doce frascos de un mes cada uno: cuatro de atorvastatina 20 mg, cuatro de placebo y cuatro vacíos, en orden aleatorio, con la intensidad diaria de los síntomas registrada en una aplicación. Cuarenta y nueve completaron el protocolo de 12 meses. Las puntuaciones de síntomas fueron mucho más altas que la línea base tanto con la estatina (16.3) como con el placebo (15.4) que en los meses sin pastilla (8.0), y la estatina y el placebo no difirieron (P = 0.388), lo que da una razón nocebo de 0.90. Ni la intensidad de los síntomas al empezar ni su alivio al dejarlo distinguieron la estatina del placebo. Seis meses después del ensayo, la mitad de los participantes había reanudado las estatinas. Esto muestra que la mayoría de los síntomas atribuidos a un fármaco real pueden ser nocebo, impulsados por la expectativa, no por la sustancia química.
Who this may not transfer to:Enrolled adults of both sexes who had stopped statins over side effects; the nocebo mechanism is not thought to be sex-specific.
The studies · 2
Howard et al. 2021, J Am Coll Cardiol · J Am Coll Cardiol
Wood et al. 2020, N Engl J Med · N Engl J Med
Digestion
El placebo abierto alivió el SII más que la ausencia de tratamiento (puntuación de mejora de 5.0 frente a 3.9)
Las personas a quienes se les dijo claramente que sus pastillas eran placebos, sin ningún fármaco en ellas, aun así se sintieron notablemente mejor que las personas a quienes no se dio nada, a lo largo de tres semanas con una afección intestinal difícil de tratar.
Un ensayo controlado aleatorizado en 80 pacientes con síndrome del intestino irritable comparó un placebo de etiqueta abierta, presentado abiertamente como pastillas inertes con una explicación de que los placebos pueden producir poderosos efectos de autocuración mente-cuerpo, frente a un control sin tratamiento que recibía la misma atención clínica. Después de tres semanas, el grupo de placebo de etiqueta abierta puntuó significativamente más alto en la Escala de Mejora Global del SII (5.0 frente a 3.9; p = 0.002) y tuvo más probabilidades de reportar un alivio adecuado de los síntomas (59 % frente a 35 %). Es un ensayo pequeño y corto en un síntoma que se reporta de forma subjetiva, y es la demostración fundacional de que los efectos placebo no requieren engaño.
The study · 1
Kaptchuk et al. 2010, PLoS One · PLoS One
Pain
El placebo de etiqueta abierta redujo el dolor de espalda crónico aproximadamente un 30 % además de la atención habitual
Las personas con dolor de espalda de larga duración que añadieron una pastilla que se les dijo que era un placebo, además de su atención normal, tuvieron menos dolor y pudieron hacer más que quienes recibieron solo la atención normal, a lo largo de tres semanas.
Un ensayo controlado aleatorizado en 97 pacientes con dolor lumbar crónico comparó tres semanas de placebo de etiqueta abierta añadido al tratamiento habitual frente al tratamiento habitual solo. El placebo de etiqueta abierta, presentado abiertamente como inerte, produjo reducciones significativas en el dolor compuesto (aproximadamente un 30 % tanto en el dolor habitual como en el máximo) y en la discapacidad de Roland-Morris, en comparación con poco cambio en el brazo de atención habitual. Un seguimiento en el que el grupo control pasó posteriormente a placebo de etiqueta abierta observó mejoras similares. Es un ensayo pequeño y corto con resultados autoinformados.
The study · 1
Carvalho et al. 2016, Pain · Pain
Energy And Fatigue
El placebo de etiqueta abierta alivió la fatiga relacionada con el cáncer en aproximadamente un 29 %
Los sobrevivientes de cáncer que tomaron una pastilla etiquetada abiertamente como placebo se sintieron menos agotados y afrontaron mejor que quienes recibieron sin tratamiento adicional, a lo largo de tres semanas.
A randomized controlled trial in 74 cancer survivors with persistent fatigue compared three weeks of open-label placebo against treatment as usual. The placebo group reported significantly greater improvement in fatigue severity (about 29%) and in fatigue-disrupted quality of life. Control participants who then took open-label placebo for three weeks showed comparable gains. The trial is small and short, and fatigue is a subjective outcome, but it extends the open-label placebo finding to a distressing symptom in a serious illness.
The study · 1
Hoenemeyer et al. 2018, Sci Rep · Sci Rep
Immune Function
The immune system learned to suppress itself on a conditioned cue
People who took an immune-suppressing drug several times alongside an unusual-tasting drink later had their immune activity drop from the drink by itself. Their bodies had learned the response.
In a controlled experiment, healthy men received the immunosuppressant drug ciclosporin A together with a novel-tasting drink over an initial learning phase. On later re-exposure to the drink alone, without the drug, they showed suppressed immune function, including reduced interleukin-2 and interferon-gamma mRNA expression and reduced lymphocyte proliferation, compared with controls. This demonstrates that a placebo response can be conditioned into the immune system, one of the two core mechanisms (alongside expectation) behind placebo effects.
Who this may not transfer to:The immune-conditioning trial enrolled only men; the conditioning mechanism is not thought to be sex-specific, but it was not measured in women.
The study · 1
Goebel et al. 2002, FASEB J · FASEB J
How It Works
The mechanisms are concrete, mapped across the nervous, endocrine and immune systems, and each is graded at the strength of its own evidence.
How a Placebo Acts on the Body
1Expectation changes what the brain does next
Expecting relief switches on specific brain systems that then act on the body. Believing a treatment will help changes what the nervous system does next. That is why the pill, the attention, and the setting matter, and why a confident explanation works better than a doubtful one.
2The pain relief runs on the body's own opioids
For pain, expectation recruits the body's own opioids, the endogenous opioids. Naloxone, which blocks opioid receptors, cancels much of placebo pain relief. Imaging shows placebo analgesia running through the same descending pathway opioid drugs use (the anterior cingulate, the periaqueductal gray, the brainstem.
3Placebo triggers dopamine release in Parkinson's
In Parkinson's, a placebo the person believes is their medication triggers dopamine release in the striatum) the neurotransmitter the disease depletes. PET scans measure it directly, and it tracks the expectation of relief.
4The body can learn a response
Conditioning is the second route. Healthy volunteers who repeatedly took an immune-suppressing drug alongside a distinctive drink later showed immune suppression from the drink alone, the body having learned the response. The reviews describe two routes working together: expectation and learning.
A calm, attentive practitioner and a clear, positive account raise expectation; a rushed or alarming one lowers it. How a treatment is framed changes its effect in the body.
The Nocebo Side
The same mechanism runs in reverse: a negative expectation produces symptoms. Being warned a treatment may cause nausea, pain or fatigue makes those symptoms more likely and more intense, through the same brain and hormone systems.
A blinded crossover trial makes the size plain. Sixty people who had stopped statins over side effects took atorvastatin, a placebo, and nothing across random months, rating symptoms daily (SAMSON 2021). Symptom scores ran much higher on statin than in the no-tablet months, and just as high on placebo, with no difference between drug and dummy. About 90% of the symptom burden they blamed on the statin also appeared on the placebo. This is why a large share of side effects reported on any drug also show up in the placebo arms of its trials.
What This Means For You
Expectation and the ritual of treatment are part of how nearly every therapy works, whether or not the drug is active, and the setting shapes the outcome.
- A treatment you trust, taken as a deliberate act with attention, gives its active part the best chance to work and adds an effect of its own.
- Open-label trials show the benefit survives being told the pill is inert, so candor and effect can go together.
- How a risk is described changes how much of it a person actually feels: a calm, accurate warning produces fewer symptoms than an alarming one.
None of this replaces an effective treatment. A placebo can ease symptoms and improve how someone functions. Calling a benefit "just placebo" is a category error: the placebo effect is a documented self-healing response, with effects on pain, mood, movement and the immune system.
Go Deeper
For how we weigh evidence like this, see how we grade evidence. For how we treat practices that are far older than the studies now testing them, see Yang Sheng and why we built this.
Common Questions
Is the placebo effect real, or just in my head?
It is real, and the brain is part of the body, so "in your head" does not make it less physical. PET scans and naloxone blockade show measurable changes in brain chemistry and hormones.
Can a placebo work if you know it is a placebo?
Yes. People handed a pill and told plainly it held no drug, with an explanation that placebos can act through mind-body pathways, still improved more than untreated people. Deception is not the active part.
Is acupuncture just a placebo?
Trials comparing real acupuncture with sham needling often find both help more than no treatment. The gap between real and sham is usually small and varies by condition, a sign of a placebo component. That does not empty acupuncture of value, and whether needling adds a specific effect on top is measured separately, case by case.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 15 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.